RGNX — REGENXBIO Inc.
Is RGNX overbought or oversold? Here is the current MarketMoodz read.
REGENXBIO Inc. (RGNX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.32. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$7.32
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
REGENXBIO is a platform-focused gene-therapy developer with meaningful upside tied to clinical milestones and partner economics, but limited current commercial revenue and exposure to financing and execution risk. Near-term market conditions favor large-cap pharma and defensive healthcare, which can pressure mid-cap, development-stage biotechs. Key drivers over the coming weeks will be cash runway visibility, any near-term clinical updates, and broader biotech financing sentiment; negative clinical or financing developments would likely push the share price materially lower, while positive trial readouts or licensing milestones could reaccelerate upside.
Key factors
- NAV AAV platform gives potential for multiple partnered revenue streams and proprietary programs, creating optionality if clinical readouts succeed
- Clinical-stage pipeline with upcoming program milestones that could drive asymmetric upside on positive outcomes
- Limited current commercial revenue; financial health sensitive to trial costs and capital markets access
- Partnerships and licensing deals can de-risk development cost and provide milestone/royalty income if executed
- Sector-wide investor preference for large-cap pharma and defensive names reduces near-term speculative biotech inflows
- Convertible-debt and financing environment could create dilution or hedging pressure for mid-cap biotech issuers
Risks
- Clinical trial failures or disappointing data for lead programs that would materially reduce valuation
- Regulatory setbacks or longer-than-expected approval timelines for gene-therapy constructs
- Manufacturing scale-up complexity and high COGS for AAV products, limiting margins and commercial timelines
- Cash runway constraints leading to dilution via equity raises or dilutive financings
- Competitive risk from larger pharma entrants and other gene-therapy platforms with deeper commercial resources
- Reimbursement uncertainty for novel gene therapies and slower-than-expected payer adoption
Latest MarketMoodz coverage
- FDA Revisits Regenxbio’s Navsunli, Paving Near-Term Catalyst2026-06-22
- REGENXBIO Pushes RGX-202 Toward Accelerated Approval in Duchenne2026-05-14
- FDA Clears Denali's Avlayah as First Brain-Penetrating Biologic2026-03-26
- Moderna, Capricor Lead Biotech Movers on FDA Shakeups and HOPE-3 Data2026-03-09
- FDA reversals unsettle Moderna and biotech peers, raise regulatory risk2026-03-06
See today's live rating, score and targets
Members see the live hourly rating for RGNX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.